A first report of radioembolization for hepatic metastases from ocular melanoma

Cancer Invest. 2009 Jul;27(6):682-90. doi: 10.1080/07357900802620893.

Abstract

Background: Ocular melanoma (OM) metastasizes to the liver and is rapidly fatal despite aggressive therapy. Yttrium-90 microspheres (radioembolization) delivered via the hepatic artery is an established and effective approach for primary and metastatic hepatic tumors, although (90)Y use in OM has not been reported previously.

Methods: A retrospective review was performed for all patients with OM who received radioembolization at 5 centers.

Results: 11 patients received 12 treatments with a median activity of 1.55 GBq delivered per treatment. Toxicity was minimal, with PET/CT at 3 months posttreatment showing a response in all patients; 1 patient had a complete response.

Conclusions: Radioembolization can control hepatic metastases of OM with very few side effects.

Publication types

  • Multicenter Study

MeSH terms

  • Adult
  • Aged
  • Angiography, Digital Subtraction
  • Brachytherapy* / adverse effects
  • Embolization, Therapeutic* / adverse effects
  • Europe
  • Eye Neoplasms / pathology*
  • Female
  • Hepatic Artery
  • Humans
  • Injections, Intra-Articular
  • Israel
  • Kaplan-Meier Estimate
  • Liver Neoplasms / mortality
  • Liver Neoplasms / radiotherapy*
  • Liver Neoplasms / secondary
  • Magnetic Resonance Imaging
  • Male
  • Melanoma / mortality
  • Melanoma / radiotherapy*
  • Melanoma / secondary
  • Microspheres
  • Middle Aged
  • Positron-Emission Tomography
  • Radiopharmaceuticals / administration & dosage
  • Radiopharmaceuticals / adverse effects
  • Radiopharmaceuticals / therapeutic use*
  • Retrospective Studies
  • Time Factors
  • Tomography, X-Ray Computed
  • Treatment Outcome
  • United States
  • Yttrium Radioisotopes / administration & dosage
  • Yttrium Radioisotopes / adverse effects
  • Yttrium Radioisotopes / therapeutic use*

Substances

  • Radiopharmaceuticals
  • Yttrium Radioisotopes